Full Press Release Details
InMed to Participate in Upcoming Virtual Investor
Vancouver, BC - May 24, 2023 - InMed Pharmaceuticals
Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development,
manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the
Company's executive team will be participating in the upcoming virtual investor events:
Tribe Public Webinar
Eric A. Adams, CEO of InMed, and Jerry Griffin, VP,
Sales and Marketing of BayMedica, will co-host a presentation event titled "Addressing The Increasing Demand For Rare Cannabinoids".
Management will be available for a 5-10 minute Q&A session at the end of the presentation. Please send your questions for management
to Tribe's email: research@tribepublic.com.
Presentation Time: 11.30 AM ET
of InMed, will present a corporate overview followed by a Q&A session. Management will be available for virtual one-on-one meetings
for qualified investors. The conference is complimentary to qualified investors. Please register through Investor Summit.
Following the events, both presentation recordings will be available on InMed's investor relations events page here.
InMed Pharmaceuticals is a global leader
in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches
to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information"
and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities
laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information
in this news release includes statements about: the increasing demand for rare cannabinoids; InMed's participation in future conferences;
being a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical
programs targeting the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing
approaches to produce cannabinoids for various market sectors.
Additionally, there are known and unknown risk factors
which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties
facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities
and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.